Neuroprotective peptide(Geropharm LLC)

Objective. To evaluate the effectiveness of complex rehabilitation measures using the peptidergic drug Cortexin in children with perinatal CNS damage based on the study of serum levels of proinflammatory cytokines. Material and methods. 146 children (86 boys, 60 girls) aged from 20 days to 6 months (the average age of boys was 2.7±1.2, and girls 2.9±1.1 months) with CNS PP were examined. Depending on the severity of CNS PP, patients were divided into 3 groups: the 1st (n=50) included patients with severe CNS PP, the 2nd (n=58) — moderate and the 3rd (n=38) — with mild severity. By random sampling, each group was divided into 2 subgroups: patients of subgroups 1A, 2A, and 3A were prescribed Cortexin in addition to standard therapy in accordance with current clinical guidelines. Patients in subgroups 1B, 2B, and 3B received only standard therapy. During the treatment, the concentration of TNF-α and IL-Iß in the blood serum was determined. Results. In subgroup 1A, the concentration of IL-Iß decreased by 1.5 times after treatment (p=0.022), and TNF-α by 1.4 times (p=0.033), which was statistically significantly higher than the similar changes in subgroup 1B. In subgroup 2A, the concentration of IL-Iß decreased by 1.4 times, TNF-α by 1.2 times (p=0.038) by 3 months (p=0.037) from baseline values, whereas in patients of subgroup 2B, no correction of cytokine levels was observed. In subgroup 3A, the dynamics of IL-Iß and TNF-α concentrations had a positive trend and exceeded similar indicators in subgroup 3B. Conclusions. In patients with CNS ASD of varying severity, the inclusion of Cortexin in treatment regimens leads to a significant shift in IL-Iß and TNF-α levels 3 months after the start of treatment, which significantly exceeds the results of standard treatment.

Objective. To assess the role of genetic polymorphisms in folate metabolism enzyme genes in the manifestation of migraine in children. Material and Methods. The study included 54 children aged 7 to 18 years with clinical manifestations of migraine. The control group consisted of 115 children without neurological disorders. Genetic analysis of four polymorphic variants of folate cycle enzyme genes was conducted: MTHFR: 677C>T (A223V C677T, rs1801133); MTHFR: 1298A>C (E429A A1298C, rs1801131); MTR: 2756A>G (A2756G, rs1805087); MTRR: 66A>G (A66G, rs1801394). In addition to genetic testing, data collection included patient complaints, medical and family histories, clinical examinations, determination of vitamin B levels (B6, B9, B12), and plasma homocysteine levels. The therapeutic effect of Cortexin (10 mg intramuscularly once daily) on the course of migraine in children was also assessed. Results. The rare homozygous 677TT genotype of the MTHFR gene was significantly more frequent in the study group (p=0.043), while the heterozygous 1298AC genotype of the MTHFR gene and the common homozygous 66AA genotype of the MTRR gene were more prevalent in the control group (p<0.05). Furthermore, levels of B vitamins (B6, B9, B12) and plasma homocysteine were measured in both groups. Children in the study group received a 10-day course of Cortexin. Conclusion. Patients with migraine showed a higher prevalence of the rare homozygous 677TT genotype of the MTHFR gene, which leads to elevated plasma homocysteine levels, often associated with latent folate deficiency. The use of «Cortexin» significantly improved the patients’ condition, reducing complaints of headaches, fatigue, and emotional instability.